TISIDB

Summary
Symbol	EED
Name	embryonic ectoderm development
Aliases	WAIT-1; HEED; WD protein associating with integrin cytoplasmic tails 1; WAIT1; Polycomb protein EED
Chromosomal Location	11q14.2-q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus. Chromosome. Note=Transiently colocalizes with XIST at inactive X chromosomes.
Domain	PF00400 WD domain
Function	Polycomb group (PcG) protein. Component of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' and 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Also recognizes 'Lys-26' trimethylated histone H1 with the effect of inhibiting PRC2 complex methyltransferase activity on nucleosomal histone H3 'Lys-27', whereas H3 'Lys-27' recognition has the opposite effect, enabling the propagation of this repressive mark. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A.

> Gene Ontology [ TOP ]
Biological Process	GO:0006349 regulation of gene expression by genetic imprinting GO:0006479 protein methylation GO:0008213 protein alkylation GO:0016570 histone modification GO:0016571 histone methylation GO:0018022 peptidyl-lysine methylation GO:0018205 peptidyl-lysine modification GO:0021510 spinal cord development GO:0031056 regulation of histone modification GO:0031058 positive regulation of histone modification GO:0031060 regulation of histone methylation GO:0031062 positive regulation of histone methylation GO:0032259 methylation GO:0034968 histone lysine methylation GO:0040029 regulation of gene expression, epigenetic GO:0043414 macromolecule methylation GO:0045814 negative regulation of gene expression, epigenetic GO:0061085 regulation of histone H3-K27 methylation GO:0061087 positive regulation of histone H3-K27 methylation GO:0070734 histone H3-K27 methylation GO:0071514 genetic imprinting GO:1902275 regulation of chromatin organization GO:1905269 positive regulation of chromatin organization
Molecular Function	GO:0003682 chromatin binding GO:0008168 methyltransferase activity GO:0008276 protein methyltransferase activity GO:0016741 transferase activity, transferring one-carbon groups GO:0042054 histone methyltransferase activity
Cellular Component	GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0000792 heterochromatin GO:0000803 sex chromosome GO:0001739 sex chromatin GO:0005720 nuclear heterochromatin GO:0031519 PcG protein complex GO:0034708 methyltransferase complex GO:0035097 histone methyltransferase complex GO:0035098 ESC/E(Z) complex GO:0044454 nuclear chromosome part GO:0045120 pronucleus

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-5619507: Activation of HOX genes during differentiation R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis R-HSA-2559583: Cellular Senescence R-HSA-2262752: Cellular responses to stress R-HSA-3247509: Chromatin modifying enzymes R-HSA-4839726: Chromatin organization R-HSA-1266738: Developmental Biology R-HSA-212165: Epigenetic regulation of gene expression R-HSA-74160: Gene Expression R-HSA-2559580: Oxidative Stress Induced Senescence R-HSA-3214841: PKMTs methylate histone lysines R-HSA-212300: PRC2 methylates histones and DNA

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-1266738: Developmental Biology
R-HSA-212165: Epigenetic regulation of gene expression
R-HSA-74160: Gene Expression
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-3214841: PKMTs methylate histone lysines
R-HSA-212300: PRC2 methylates histones and DNA

Summary
Symbol	EED
Name	embryonic ectoderm development
Aliases	WAIT-1; HEED; WD protein associating with integrin cytoplasmic tails 1; WAIT1; Polycomb protein EED
Chromosomal Location	11q14.2-q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between EED and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between EED and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26567139	Colon Carcinoma	Inhibit immunity (infiltration)	We found that PRC2 components and demethylase JMJD3-mediated histone H3 lysine 27 trimethylation (H3K27me3) repress the expression and subsequent production of Th1-type chemokines CXCL9 and CXCL10, mediators of effector T-cell trafficking. Moreover, the expression levels of PRC2 components, including EZH2, SUZ12, and EED, were inversely associated with those of CD4, CD8, and Th1-type chemokines in human colon cancer tissue, and this expression pattern was significantly associated with patient survival.

Summary
Symbol	EED
Name	embryonic ectoderm development
Aliases	WAIT-1; HEED; WD protein associating with integrin cytoplasmic tails 1; WAIT1; Polycomb protein EED
Chromosomal Location	11q14.2-q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of EED in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	EED
Name	embryonic ectoderm development
Aliases	WAIT-1; HEED; WD protein associating with integrin cytoplasmic tails 1; WAIT1; Polycomb protein EED
Chromosomal Location	11q14.2-q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of EED in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.009	0.972
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.17	0.92
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.101	0.941
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.022	0.926
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.186	0.902
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.181	0.921
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.3	0.356
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.104	0.94
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.485	0.742
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.013	0.991
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.031	0.987
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.072	0.222

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of EED in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	4.1	3.3	0.61
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	5.1	2.3	0.647
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	EED
Name	embryonic ectoderm development
Aliases	WAIT-1; HEED; WD protein associating with integrin cytoplasmic tails 1; WAIT1; Polycomb protein EED
Chromosomal Location	11q14.2-q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EED. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	EED
Name	embryonic ectoderm development
Aliases	WAIT-1; HEED; WD protein associating with integrin cytoplasmic tails 1; WAIT1; Polycomb protein EED
Chromosomal Location	11q14.2-q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EED. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EED. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	EED
Name	embryonic ectoderm development
Aliases	WAIT-1; HEED; WD protein associating with integrin cytoplasmic tails 1; WAIT1; Polycomb protein EED
Chromosomal Location	11q14.2-q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EED. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	EED
Name	embryonic ectoderm development
Aliases	WAIT-1; HEED; WD protein associating with integrin cytoplasmic tails 1; WAIT1; Polycomb protein EED
Chromosomal Location	11q14.2-q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of EED expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	EED
Name	embryonic ectoderm development
Aliases	WAIT-1; HEED; WD protein associating with integrin cytoplasmic tails 1; WAIT1; Polycomb protein EED
Chromosomal Location	11q14.2-q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between EED and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	EED
Name	embryonic ectoderm development
Aliases	WAIT-1; HEED; WD protein associating with integrin cytoplasmic tails 1; WAIT1; Polycomb protein EED
Chromosomal Location	11q14.2-q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting EED collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse EED